铂类药物在对卡铂发生过敏反应的复发性卵巢癌患者中的再应用。
Readministration of Platinum Agents in Recurrent Ovarian Cancer Patients Who Developed Hypersensitivity Reactions to Carboplatin.
机构信息
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan
出版信息
In Vivo. 2019 Nov-Dec;33(6):2045-2050. doi: 10.21873/invivo.11702.
BACKGROUND/AIM: Hypersensitivity reactions (HSRs) to carboplatin, a key drug for ovarian cancer patients, are problematic. The aim of this study was to evaluate the efficacy and safety of readministration of platinum agents (PTs) in recurrent ovarian cancer patients who developed HSRs to carboplatin.
PATIENTS AND METHODS
Thirty-one patients with recurrent ovarian cancer who developed HSRs to carboplatin were divided into those who continued to receive PTs in the following cycle (continuation group, n=24) and those in whom either the drug was switched to non-platinum agents (non-PTs) or chemotherapy was ended (discontinuation group, n=7). Outcomes were evaluated based on patients' medical records.
RESULTS
The median survival time following HSRs was 28.1 and 15.4 months in the continuation and discontinuation groups, respectively (p=0.018). In the continuation group, a total of 155 cycles of PTs were re-administrated, and 50 cycles (32%) led to recurrent HSRs. There were no recurrent HSRs with a severity of grade 3 or greater.
CONCLUSION
Continuation of PTs in ovarian cancer patients may contribute to improvement in their overall survival without severe recurrent HSRs.
背景/目的：卡铂是卵巢癌患者的关键药物，过敏反应（HSR）是一个问题。本研究旨在评估在对卡铂发生 HSR 的复发性卵巢癌患者中重新使用铂类药物（PTs）的疗效和安全性。
患者和方法
31 例对卡铂发生 HSR 的复发性卵巢癌患者分为在后续周期继续接受 PTs 治疗的患者（继续组，n=24）和药物转换为非铂类药物（非-PTs）或化疗结束的患者（停药组，n=7）。根据患者的病历评估结局。
结果
在发生 HSR 后，继续组和停药组的中位生存时间分别为 28.1 个月和 15.4 个月（p=0.018）。在继续组中，共重新给予了 155 个周期的 PTs，其中 50 个周期（32%）导致 HSR 复发。没有出现 3 级或更高级别的复发性 HSR。
结论
在卵巢癌患者中继续使用 PTs 可能有助于改善总体生存，而不会出现严重的复发性 HSR。
Zotero 插件